Yicura BioMed Advances Dual Capital and Industrial Strategy： Completes First Closing of Series B Financing Led by Gobi Partners
Full story
Yicura BioMed has completed the first closing of its Series B financing led by Gobi Partners. The clinical-stage immunotherapy company is based in the Hong Kong Science Park. It develops medicines for inflammatory diseases, cancers, and infectious diseases. The company is using this capital to advance its core product, ICVAX, for HIV and its cancer immunotherapy pipeline.
Advancing Core Product ICVAX® for HIV & Immunotherapy Pipeline for Cancers HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed (“Yicura“), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of […]